Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
John P. Leonard(Cornell University), Geoffrey I. Shapiro(Brigham and Women's Hospital)
Cited by 297
Related Papers
A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck
|Clinical Cancer Research|2004|67
Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in<i>KRAS</i>-mutant non-small cell lung cancer
|Oncotarget|2018|54
STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer
|npj Breast Cancer|2022|33
STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in <i>BRCA</i> -associated breast cancer
|bioRxiv (Cold Spring Harbor Laboratory)|2021|5